Seward simplifies cell preparation

Published: 31-May-2011
Manufacturing

Enhances applications for Strainer bags to include sterile processing of tissue samples

Seward Limited, the UK manufacturer of the Stomacher paddle blenders and accessories used in sample preparation for microbiological analyses, has further enhanced the applications for its Strainer bags to include sterile processing of tissue samples for primary cell preparation.

Gamma irradiated sterile and available in a range of sizes, the Strainer bags are compatible with all laboratory paddle blenders, including Seward’s Stomacher 80 Biomaster series. Because they are fully containable and easily used in a sterile environment, the Strainer bags can be used for new applications in cell culture.

The 0.5mm pore size of the integrated strainer element within the Seward Strainer bag generates a uniformly homogenous cell suspension, says the Worthing-based company. This allows the cells’ passage through the pores of the central straining matrix and prevents contamination with undigested extracellular material, which can block pipettes. Produced to provide a sterile, secure environment for the preparation of single cell suspensions, the Strainer bag is suitable for the individual processing of a large number of samples.

“The new life-science applications of our robust Strainer bag technology represent the continuing, customer oriented, development to which Seward is committed,” said Stuart Ray, technical director at Seward Ltd.

“Cell scientists can simplify their primary culture preparations by straining the processed tissues to ensure trouble-free pipetting, whilst also increasing the viability of the cells produced as the end product.”

See more

You may also like

Manufacturing

Seward moves to new premises

Read more
Doubles manufacturing and storage facilities

Trending Articles

  1. FDA issues first cGMP warning letter citing AI misuse in pharmaceutical manufacturing A Michigan-based lab has become the subject of the FDA's first dedicated enforcement action on artificial intelligence misuse in drug manufacturing — a landmark event with far-reaching implications for cGMP compliance across the pharmaceutical supply chain
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
  3. Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
  4. Lonza delivers strong performance in Q1 2026 in line with expectations and confirms full-year Outlook 2026 Basel, Switzerland, 8 May 2026 – In its qualitative Q1 2026 business update, Lonza1 reported a strong performance across its CDMO business in line with the expected trajectory for Full-Year 2026. As expected, due to a lower prior year base, campaign timing and product releases, and planned site shutdowns, CER sales growth and CORE EBITDA margin will be notably stronger in the first half of 2026 than in the second half
  5. Piramal Pharma Solutions unveils state-of-the-art payload-linker suite at its Riverview, Michigan facility The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialised solutions for payload-linkers. This cutting-edge suite will significantly enhance the company’s ability to support global payload-linker development and manufacturing and help partners bring complex therapies like antibody-drug conjugates (ADCs) and other bioconjugates to market

Upcoming event

Cleanroom Technology Conference UK

20-21 May 2026 | Conference and Exhibition | Birmingham, UK See all

You may also like

Manufacturing

Seward moves to new premises

Doubles manufacturing and storage facilities
Manufacturing

Replacing discontinued OEM degasser modules

Biotech Fluidics introduces direct replacement OEM degasser modules based on upgraded vacuum technology to support continued fluidic instrument supply without costly redesigns
Manufacturing

etherna's mRNA and LNP platforms advance Dropshot Therapeutics' renal disease programme to clinical stage

etherna has announced that partner Dropshot Therapeutics has validated its platforms in preclinical renal disease research and will now progress to IND-enabling studies, with etherna providing GMP manufacturing support ahead of planned Phase I clinical trials in 2027
Manufacturing

CARBOGEN AMCIS introduces SPRINT for early-phase development

A new, phase-appropriate approach designed to accelerate early-phase progression while maintaining scientific rigour
Manufacturing

FUJIFILM Cellular Dynamics opens new iPSC manufacturing facility in US

The new site will serve as the company's headquarters and will increase Fujifilm's capacity for induced pluripotent stem cell development and manufacturing, as demand increases with new approach methods in research
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

From bespoke to scalable: closing the manufacturing gap in advanced therapeutics

Dr Kevin Robinson (KSR) spoke to Cytiva’s Nicolas Pivet (NP), Vice President of Manufacturing and Digital Solutions, to find out how digitalisation and scalable manufacturing platforms are shaping the next phase of advanced therapeutics
Manufacturing

Piramal Pharma Solutions announces partnership with Botanix to support drug substance development

Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra. Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axillary hyperhidrosis. Through this partnership, Piramal Pharma Solutions will leverage the strength of its North American drug substance facilities to support robust, consistent patient access to Sofdra
Subscribe now